As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo

Submitted by admin on September 13, 2019 - 10:56am
Source: 
Pharmaforum
News Tags: 
Roche
Perjeta
Herceptin
Genentech
HER2-positive breast cancer
Headline: 
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
snippet: 

A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown.

Do Not Allow Advertisers to Use My Personal information